Literature DB >> 19931229

Characterization of cannabinoid-1 receptors in the locus coeruleus: relationship with mu-opioid receptors.

Jillian L Scavone1, Ken Mackie, Elisabeth J Van Bockstaele.   

Abstract

The locus coeruleus (LC)-norepinephrine system is a target of both cannabinoid and opioid actions. The present study investigated the anatomical distribution of cannabinoid-1 receptor (CB1r) in the LC and its association with mu-opioid receptor (MOR). Immunoreactivity for CB1r was localized to pre- and postsynaptic cellular profiles in the LC, 82% of which were dual-labeled for tyrosine hydroxylase (TH). Of the CB1r-immunoreactive structures, 66% were somatodendritic profiles, 22% were axon terminals, and the remaining 12% were associated with glial and small unmyelinated axon-like structures. CB1r immunoreactivity (-ir) in somatodendritic profiles was more often localized to the cytoplasm, whereas CB1r-ir located in axon terminals was more commonly localized on the plasma membrane. Somatodendritic profiles with CB1r-ir typically received input from axon terminals forming asymmetric-type synapses. In contrast, presynaptic profiles with CB1r-ir typically formed symmetric synaptic specializations. Anatomical studies confirmed the co-existence of MOR and CB1r-ir in common somatodendritic compartments of catecholaminergic neurons in the LC, and also revealed CB1r-positive axon terminals forming synaptic contact with MOR-containing dendrites. Our results provide evidence for a heterogeneous distribution of CB1r in the LC and demonstrate that CB1r and MOR co-exist in cellular profiles in this region. These data suggest important potential interactions between cannabinoid and opioid systems in LC neuronal profiles that may impact noradrenergic tone. (c) 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19931229      PMCID: PMC2835571          DOI: 10.1016/j.brainres.2009.11.023

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  70 in total

Review 1.  Molecular control of locus coeruleus neurotransmission.

Authors:  E J Nestler; M Alreja; G K Aghajanian
Journal:  Biol Psychiatry       Date:  1999-11-01       Impact factor: 13.382

2.  Ultrastructural evidence for co-localization of corticotropin-releasing factor receptor and mu-opioid receptor in the rat nucleus locus coeruleus.

Authors:  Beverly A S Reyes; Julia D Glaser; Elisabeth J Van Bockstaele
Journal:  Neurosci Lett       Date:  2006-12-15       Impact factor: 3.046

3.  Repeated cannabinoid administration increases indices of noradrenergic activity in rats.

Authors:  M E Page; V C Oropeza; S E Sparks; Y Qian; A S Menko; E J Van Bockstaele
Journal:  Pharmacol Biochem Behav       Date:  2007-01-09       Impact factor: 3.533

4.  Brain norepinephrine rediscovered in addiction research.

Authors:  Gary Aston-Jones; Peter W Kalivas
Journal:  Biol Psychiatry       Date:  2008-06-01       Impact factor: 13.382

Review 5.  There and back again: a tale of norepinephrine and drug addiction.

Authors:  David Weinshenker; Jason P Schroeder
Journal:  Neuropsychopharmacology       Date:  2006-12-13       Impact factor: 7.853

6.  Repeated cannabinoid injections into the rat periaqueductal gray enhance subsequent morphine antinociception.

Authors:  Adrianne R Wilson; Lauren Maher; Michael M Morgan
Journal:  Neuropharmacology       Date:  2008-08-05       Impact factor: 5.250

7.  Regulation of CB1 cannabinoid receptor trafficking by the adaptor protein AP-3.

Authors:  Raphael Rozenfeld; Lakshmi A Devi
Journal:  FASEB J       Date:  2008-02-11       Impact factor: 5.191

8.  Local administration of a cannabinoid agonist alters norepinephrine efflux in the rat frontal cortex.

Authors:  M E Page; V C Oropeza; E J Van Bockstaele
Journal:  Neurosci Lett       Date:  2007-11-09       Impact factor: 3.046

9.  Low dose combination of morphine and delta9-tetrahydrocannabinol circumvents antinociceptive tolerance and apparent desensitization of receptors.

Authors:  Paul A Smith; Dana E Selley; Laura J Sim-Selley; Sandra P Welch
Journal:  Eur J Pharmacol       Date:  2007-06-12       Impact factor: 4.432

10.  mu-Opioid receptor forms a functional heterodimer with cannabinoid CB1 receptor: electrophysiological and FRET assay analysis.

Authors:  Minoru Hojo; Yuka Sudo; Yuko Ando; Koichiro Minami; Masafumi Takada; Takehiro Matsubara; Masato Kanaide; Kohtaro Taniyama; Koji Sumikawa; Yasuhito Uezono
Journal:  J Pharmacol Sci       Date:  2008-11-13       Impact factor: 3.337

View more
  36 in total

Review 1.  Cannabinoid modulation of noradrenergic circuits: implications for psychiatric disorders.

Authors:  Ana Franky Carvalho; Elisabeth J Van Bockstaele
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-01-24       Impact factor: 5.067

2.  Gi/o-coupled receptors compete for signaling to adenylyl cyclase in SH-SY5Y cells and reduce opioid-mediated cAMP overshoot.

Authors:  Erica S Levitt; Lauren C Purington; John R Traynor
Journal:  Mol Pharmacol       Date:  2010-11-22       Impact factor: 4.436

3.  Intracellular cannabinoid type 1 (CB1) receptors are activated by anandamide.

Authors:  G Cristina Brailoiu; Tudor I Oprea; Pingwei Zhao; Mary E Abood; Eugen Brailoiu
Journal:  J Biol Chem       Date:  2011-06-30       Impact factor: 5.157

Review 4.  Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal.

Authors:  J L Scavone; R C Sterling; E J Van Bockstaele
Journal:  Neuroscience       Date:  2013-04-24       Impact factor: 3.590

5.  Safety of oral dronabinol during opioid withdrawal in humans.

Authors:  Crystal J Jicha; Michelle R Lofwall; Paul A Nuzzo; Shanna Babalonis; Samy Claude Elayi; Sharon L Walsh
Journal:  Drug Alcohol Depend       Date:  2015-10-09       Impact factor: 4.492

6.  Cortical adrenoceptor expression, function and adaptation under conditions of cannabinoid receptor deletion.

Authors:  B A S Reyes; A F Carvalho; P Szot; D J Kalamarides; Q Wang; L G Kirby; E J Van Bockstaele
Journal:  Exp Neurol       Date:  2017-03-21       Impact factor: 5.330

7.  Therapeutic potential of opioid/cannabinoid combinations in humans: Review of the evidence.

Authors:  Shanna Babalonis; Sharon L Walsh
Journal:  Eur Neuropsychopharmacol       Date:  2020-04-06       Impact factor: 4.600

Review 8.  Interaction of Cannabis Use and Aging: From Molecule to Mind.

Authors:  Hye Bin Yoo; Jennifer DiMuzio; Francesca M Filbey
Journal:  J Dual Diagn       Date:  2019-09-30

9.  Opioid withdrawal suppression efficacy of oral dronabinol in opioid dependent humans.

Authors:  Michelle R Lofwall; Shanna Babalonis; Paul A Nuzzo; Samy Claude Elayi; Sharon L Walsh
Journal:  Drug Alcohol Depend       Date:  2016-05-10       Impact factor: 4.492

Review 10.  Drug discovery strategies that focus on the endocannabinoid signaling system in psychiatric disease.

Authors:  Ryan Wyrofsky; Paul McGonigle; Elisabeth J Van Bockstaele
Journal:  Expert Opin Drug Discov       Date:  2014-12-09       Impact factor: 6.098

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.